NCT02636322View on ClinicalTrials.gov

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 29, 2016

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions

Diffuse Large B-Cell Lymphoma Unclassifiable

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

DRUG

Ibrutinib

Given PO

DRUG

Lenalidomide

Given PO

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02636322 - Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | Biotech Hunter | Biotech Hunter